The incidence of COX-2 expression in breast cancer ranges from 5% to 90%, with high expression in patients with a poor prognosis [79], highly malignant breast cancer [80], and HER2/neu-positive tumor [81]. This evidence concerns the gene ERBB2 and breast carcinoma.